Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) Short Interest Up 289.0% in June

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) saw a large growth in short interest during the month of June. As of June 30th, there was short interest totaling 602,285 shares, a growth of 289.0% from the June 15th total of 154,817 shares. Based on an average daily volume of 18,970,380 shares, the days-to-cover ratio is currently 0.0 days. Approximately 12.9% of the company’s stock are short sold.

Creative Medical Technology Trading Down 6.3%

CELZ traded down $0.06 during trading on Monday, hitting $0.85. 308,890 shares of the company’s stock traded hands, compared to its average volume of 1,597,671. The stock has a market capitalization of $4.05 million, a price-to-earnings ratio of -0.40 and a beta of 1.89. The company’s 50 day simple moving average is $1.94 and its two-hundred day simple moving average is $1.99. Creative Medical Technology has a 12-month low of $0.79 and a 12-month high of $6.25.

Creative Medical Technology (NASDAQ:CELZ) last posted its quarterly earnings results on Friday, May 8th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.01. On average, equities analysts expect that Creative Medical Technology will post -1.14 EPS for the current year.

Hedge Funds Weigh In On Creative Medical Technology

An institutional investor recently bought a new position in Creative Medical Technology stock. Jane Street Group LLC purchased a new stake in shares of Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 30,205 shares of the company’s stock, valued at approximately $59,000. Jane Street Group LLC owned about 1.17% of Creative Medical Technology as of its most recent SEC filing. 1.42% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Creative Medical Technology in a report on Friday, May 22nd. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Reduce”.

About Creative Medical Technology

Creative Medical Technology Holdings, Inc (NASDAQ: CELZ) is a clinical‐stage biotechnology company focused on the development, manufacture and commercialization of exosome‐based therapies derived from human bone marrow mesenchymal stem cells. The company’s proprietary exosome platform is being investigated for applications in regenerative medicine, aesthetic dermatology, wound healing and anti‐inflammatory treatments. Creative Medical leverages cGMP manufacturing processes to produce sterile, cell‐free exosome formulations designed to support tissue repair and cellular rejuvenation.

The company’s lead product candidates include XoFlo, an exosome enrichment product intended for use in musculoskeletal and soft tissue injuries, and specialized formulations targeting skin rejuvenation and scar reduction.